Verona Pharma’s interim results highlight a busy period for the group. Positive headline data from the group’s Phase IIa asthma trial of RPL554 and Phase IIa ‘add-on’ trial in COPD were reported. The impressive data followed the stellar Phase I/II trial results with the new nebulised formulation of RPL554 in 2015. The recent £44.7m equity capital raise enables the group to progress its development of RPL554 through to a Phase III ready stage. If development goes according to plan, RPL554 could b ....
